| Symbol | ACLX |
|---|---|
| Name | ARCELLX, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 25 WEST WATKINS MILL ROAD,SUITE A, GAITHERSBURG, Maryland, 20878, United States |
| Telephone | +1 240 327-0603 |
| Fax | — |
| — | |
| Website | https://www.arcellx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Additional info from NASDAQ: |
New Form SC 14D9/A - Arcellx, Inc. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001104659-26-045754 <b>Size:</b> 55 KB
Read moreNew Form SC 14D9/A - Arcellx, Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001104659-26-044662 <b>Size:</b> 21 KB
Read moreNew Form SC TO-T/A - Arcellx, Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001104659-26-044653 <b>Size:</b> 67 KB
Read moreNew Form SC 14D9/A - Arcellx, Inc. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001104659-26-038581 <b>Size:</b> 28 KB
Read moreNew Form SC TO-T/A - Arcellx, Inc. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001104659-26-038557 <b>Size:</b> 75 KB
Read moreNew Form SCHEDULE 13G/A - Arcellx, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000638 <b>Size:</b> 7 KB
Read moreGilson Michelle 🔴 sold 5.0K shares of Arcellx, Inc. (ACLX) Transaction Date: Mar 17, 2026 | Filing ID: 116340
Read moreNew Form SC 14D9 - Arcellx, Inc. <b>Filed:</b> 2026-03-06 <b>AccNo:</b> 0001104659-26-024793 <b>Size:</b> 809 KB
Read moreNew Form SC TO-T - Arcellx, Inc. <b>Filed:</b> 2026-03-06 <b>AccNo:</b> 0001104659-26-024755 <b>Size:</b> 4 MB
Read moreNew Form SCHEDULE 13G/A - Arcellx, Inc. <b>Filed:</b> 2026-03-06 <b>AccNo:</b> 0001897612-26-000310 <b>Size:</b> 7 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06626919 | A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With… | Phase1 | Muscular Diseases | Recruiting | 2025-04-30 | 2028-04-01 | ClinicalTrials.gov |
| NCT06413498 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Part… | Phase3 | Multiple Myeloma | Recruiting | 2024-08-23 | 2031-07-01 | ClinicalTrials.gov |
| NCT05457010 | Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or … | Phase1 | Acute Myeloid Leukemia | Recruiting | 2022-11-28 | 2025-11-17 | ClinicalTrials.gov |
| NCT05396885 | Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2022-07-15 | 2026-12-01 | ClinicalTrials.gov |
| NCT04155749 | Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Mul… | Phase1 | Relapsed and Refractory Multiple Myeloma | Active_Not_Recruiting | 2019-12-23 | 2027-05-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Standard Lymphodepletion regimen | DRUG | Phase PHASE1 | Muscular Diseases | RECRUITING | NCT06626919 |
| anito-cel | BIOLOGICAL | Phase PHASE1 | Muscular Diseases | RECRUITING | NCT06626919 |
| Carfilzomib | DRUG | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06413498 |
| Daratumumab | DRUG | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06413498 |
| Dexamethasone | DRUG | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06413498 |
| Bortezomib | DRUG | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06413498 |
| Pomalidomide | DRUG | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06413498 |
| Fludarabine | DRUG | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06413498 |
| Cyclophosphamide | DRUG | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06413498 |
| Anitocabtagene Autoleucel | DRUG | Phase PHASE3 | Multiple Myeloma | RECRUITING | NCT06413498 |
| ARC-T Cells | BIOLOGICAL | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05457010 |
| SPRX002 | BIOLOGICAL | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05457010 |
| anitocabtagene-autoleucel | BIOLOGICAL | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05396885 |